# EDGAR Filing Document

**Accession Number:** 0001012477
**File Stem:** 0001104659-26-014341
**Filing Date:** 2026-2
**Character Count:** 10292
**Document Hash:** cb56e0134f6b7f1697554a67b7f2e22e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-014341.hdr.sgml**: 20260212

**ACCESSION NUMBER**: 0001104659-26-014341

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260212

**DATE AS OF CHANGE**: 20260212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVADEL PHARMACEUTICALS PLC
- **CENTRAL INDEX KEY:** 0001012477
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-267198
- **FILM NUMBER:** 26627076

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10 EARLSFORT TERRACE
- **CITY:** DUBLIN 2
- **PROVINCE COUNTRY:** L2
- **ZIP:** D02 T380
- **BUSINESS PHONE:** 636-449-1830

**MAIL ADDRESS:**
- **STREET 1:** 16640 CHESTERFIELD GROVE ROAD
- **STREET 2:** SUITE 200
- **CITY:** CHESTERFIELD
- **STATE:** MO
- **ZIP:** 63005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLAMEL TECHNOLOGIES SA
- **DATE OF NAME CHANGE:** 19960422

**As filed with the Securities and Exchange Commission on February 12, 2026**

**Registration No. 333-289355**

**Registration No. 333-267198**

**Registration No. 333-237962**

**Registration No. 333-236258**

**Registration No. 333-183961**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-289355**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-267198**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-237962**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-236258**

**POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-3 REGISTRATION STATEMENT NO. 333-183961**

 ****

***UNDER***

***THE SECURITIES ACT OF 1933***

**AVADEL PHARMACEUTICALS PLC**

**(Exact name of Registrant as Specified in Its Charter)** 

---

| | |
|:---|:---|
| **Ireland** | **98-1341933** |
| **(State or other jurisdiction of<br> Incorporation or organization)** | **(I.R.S. Employer<br> Identification No.)** |

---

**10 Earlsfort Terrace**

**Dublin 2, Ireland, D02 T380**

**+353-1-901-5201**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**c/o Alkermes plc**

**David J. Gaffin, Esq.**

**Connaught House**

**1 Burlington Road**

**Dublin 4, Ireland D04 C5Y6**

**(Name and address of agent for service)**

**+353-1-772-8000**

**(Telephone number, including area code, of agent for service)**

***Copies to:***

**Chelsea N. Darnell, Esq.**

**Paul, Weiss, Rifkind, Wharton & Garrison LLP**

**1285 Avenue of the Americas**

**New York, New York 10019-6064**

**(212) 373-3000**

**Stephen FitzSimons, Esq.**

**McCann FitzGerald LLP**

**Riverside One, Sir John Rogerson's Quay**

**Dublin 2, D02 X576, Ireland**

**+353-1-829-0000**

**Approximate date of commencement of proposed sale to the public:** Not applicable. Removal from registration of securities that were not sold pursuant to the registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ¨

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ¨

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ◻ |
| Non-accelerated filer | ◻ | Smaller reporting Registrant | ◻ |
|  |  | Emerging growth Registrant | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

**DEREGISTRATION OF UNSOLD SECURITIES**

These Post-Effective Amendments (the "Post-Effective Amendments") relate to the following Registration Statements of Avadel Pharmaceuticals plc, a public limited company organized under the laws of Ireland (the "Registrant") and Flamel Technologies, S.A. (the "Predecessor Issuer") on Form S-3 and Form F-3 (collectively, the "Registration Statements"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· [Registration Statement on Form S-3 (File No. 333- 289355) filed with the Securities and Exchange Commission (the "SEC") by the Registrant on August 7, 2025;](http://www.sec.gov/Archives/edgar/data/1012477/000110465925075177/tm2522608-1_s3asr.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· [Registration Statement on Form S-3 (File No. 333-267198) filed with the SEC by the Registrant on August 31, 2022;](http://www.sec.gov/Archives/edgar/data/1012477/000110465922096576/tm2224869d1_s3.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· [Registration Statement on Form S-3 (File No. 333-237962) filed with the SEC by the Registrant on May 1, 2020;](http://www.sec.gov/Archives/edgar/data/1012477/000110465920055587/tm2018177d1_s3.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· [Registration Statement on Form S-3 (File No. 333-236258) filed with the SEC by the Registrant on February 5, 2020; and](http://www.sec.gov/Archives/edgar/data/1012477/000110465920010987/tm206262-1_s3.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· [Registration Statement on Form F-3 (File No. 333-183961) filed with the SEC by the Predecessor Issuer on September 18, 2012](http://www.sec.gov/Archives/edgar/data/1012477/000114420412051888/v323884_f3.htm) , as amended
by that [Post-Effective Amendment No. 1, filed with the SEC on September 30, 2016](http://www.sec.gov/Archives/edgar/data/1012477/000114420416126297/v449544_posam.htm) , and that [Post-Effective Amendment No. 2, filed with the SEC on January 6, 2017](http://www.sec.gov/Archives/edgar/data/1012477/000114420417001055/v456290_posam.htm) .

The Registrant is filing these Post-Effective Amendments to the Registration Statements to deregister all securities that remain unsold under the Registration Statements.

On February 12, 2026, pursuant to the Transaction Agreement, dated October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement, dated November 18, 2025 (as amended, the "Transaction Agreement"), by and between the Registrant and Alkermes plc ("Alkermes"), Alkermes acquired the Registrant pursuant to a court-sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme"). As a result of the Scheme, the Registrant became a wholly owned subsidiary of Alkermes.

As a result of the consummation of the transactions contemplated by the Transaction Agreement, Registrant has terminated any and all of the offerings of Registrant's securities pursuant to the Registration Statements. In accordance with the undertakings made by Registrant to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offerings, Registrant hereby amends the Registration Statements and removes from registration any and all of the securities of Registrant registered under the Registration Statements that remain unsold as of the date of these Post-Effective Amendments, and hereby terminates the effectiveness of the Registration Statements.

The foregoing description of the Transaction Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Transaction Agreement, which is attached as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the SEC on October 22, 2025, and Amendment No. 1 to the Transaction Agreement, which is attached as Exhibit 2.2 to the Company's Current Report on Form 8-K filed with the SEC on November 19, 2025.

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused these Post-Effective Amendments to the Registration Statements described above to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, in the Country of Ireland on February 12, 2026.

AVADEL PHARMACEUTICALS PLC

---

| | |
|:---|:---|
| By: | /s/ Declan O'Connor |
|  | Declan O'Connor |
|  | Director |

---

No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.